Most LMICs use the much cheaper native E. coli asparaginase, to which allergic reactions (20%–42% of patients with ALL) and neutralising antibody formation (in another 30%–40%) are much common. This evidence concerns the gene ASPG and acute lymphoblastic leukemia.